AtriCure Inc
NASDAQ:ATRC

Watchlist Manager
AtriCure Inc Logo
AtriCure Inc
NASDAQ:ATRC
Watchlist
Price: 30.54 USD 0.13%
Market Cap: 1.5B USD
Have any thoughts about
AtriCure Inc?
Write Note

Operating Margin
AtriCure Inc

-7.6%
Current
5%
Average
4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-7.6%
=
Operating Profit
-34.2m
/
Revenue
447.6m

Operating Margin Across Competitors

Country US
Market Cap 1.5B USD
Operating Margin
-8%
Country US
Market Cap 199.5B USD
Operating Margin
17%
Country US
Market Cap 190.6B USD
Operating Margin
26%
Country US
Market Cap 140.3B USD
Operating Margin
22%
Country US
Market Cap 133.7B USD
Operating Margin
18%
Country IE
Market Cap 104.5B USD
Operating Margin
19%
Country US
Market Cap 65.8B USD
Operating Margin
14%
Country DE
Market Cap 58.1B EUR
Operating Margin
12%
Country US
Market Cap 44.3B USD
Operating Margin
28%
Country CN
Market Cap 308.3B CNY
Operating Margin
36%
Country US
Market Cap 36.4B USD
Operating Margin
13%
No Stocks Found

AtriCure Inc
Glance View

Market Cap
1.5B USD
Industry
Health Care

Nestled in the heart of the highly competitive medical device industry, AtriCure Inc. has carved a significant niche for itself by focusing on the surgical treatment of atrial fibrillation, a common and potentially serious heart rhythm disorder. Founded in 2000 and headquartered in Mason, Ohio, AtriCure designs, manufactures, and sells an array of surgical devices aimed at improving treatment outcomes for this condition. The company’s innovative technology targets the complex network of electrical signals in the heart to restore regular rhythm and mitigate the risk of stroke—a common consequence of untreated atrial fibrillation. By providing surgeons with minimally invasive tools and advanced cryoablation and radiofrequency therapy systems, AtriCure not only addresses surgical efficiency but also enhances patient recovery times, distinguishing itself from its competitors. AtriCure derives its revenue from the sale of these sophisticated products directly to hospitals and surgical centers both in the United States and internationally. Key components of its portfolio include the Synergy Ablation System, which is acclaimed for its precision in creating lesions that block erratic electrical pathways, and AtriClip, a line of devices designed to occlude the left atrial appendage, thereby reducing stroke risk. As healthcare providers increasingly recognize the benefits of surgical intervention for atrial fibrillation over alternative treatments, AtriCure's financial health is buoyed by the rising adoption of its products. The company's strategic focus on expanding its product pipeline and enhancing its global sales footprint underscores its commitment to continuous growth and innovation in cardiac care.

ATRC Intrinsic Value
51 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-7.6%
=
Operating Profit
-34.2m
/
Revenue
447.6m
What is the Operating Margin of AtriCure Inc?

Based on AtriCure Inc's most recent financial statements, the company has Operating Margin of -7.6%.